2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 855

Identification of a Burkholderia-Like Strain From Temporal Arteries of Subjects with Giant Cell Arteritis
Abstract Number: 553

Identification of Axial Spondyloarthritis Among Patients with Chronic Back Pain in Primary Care – How Does Determination of HLA B27 Influence the Performance of Clinical Assessments of Inflammatory Back Pain?
Abstract Number: 2478

Identification of Disease-Specific Neuroimaging Phenotypes in Childhood Inflammatory Brain Diseases
Abstract Number: 1195

Identification of Follicular Helper T Cells As a Novel Cell Population Potentially Involved in the Pathogenesis of Rheumatoid Arthritis
Abstract Number: 2108

Identification of Four Parameters That Drive the Discordance Between the Patient and Physician Global Assessment in Rheumatoid Arthritis
Abstract Number: 1062

Identification of Highly Potent and Selective Interleukin-1 Receptor-Associated Kinase 4 Inhibitors for the Treatment of Rheumatic Diseases
Abstract Number: 999

Identification of New Epistatic Interactions with the HLA Region in the Genetic Etiology of Psoriasis and Psoriatic Arthritis
Abstract Number: 2166

Identification of Serological Biomarker Profiles Associated with Response to IL-6 Intervention in Rheumatoid Arthritis
Abstract Number: 974

Identification of Susceptibility Loci for Inflammatory Arthritis
Abstract Number: 1774

Identification of Target Antigens of Anti-Endothelial Cell Antibodies in Patients with ANCA-Associated Systemic Vasculitis: A Proteomic Approach
Abstract Number: 1792

Identification of the Antimicrobial Peptide LL-37 As a Potential Mediator of Synovial Inflammation in Rheumatoid Arthritis
Abstract Number: 1606

Identifying a Link Between Uranium Exposure and Systemic Lupus Erythematosus in a Community Living near a Uranium Plant
Abstract Number: 2095

Identifying Arthralgia Patients At Risk for Rheumatoid Arthritis in the Rotterdam Early Arthritis Cohort
Abstract Number: 1857

Identifying Core Symptom Domains in the Fibromyalgia Impact Questionnaire: Principal Component Analysis of Data From Milnacipran Clinical Studies
Abstract Number: 1122

Identifying Radiographic Phenotypes of Early Knee Osteoarthritis Using Separate Quantitative Features Might Improve Patient Selection for More Targeted Treatment

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].